In this study, after treatment, the total effective rate (84.00%) of the combined group was significantly higher than that of the control group (52.94%), and after treatment, the levels of CD3+, CD4+, CD4+/CD8+, and Treg in the combined group were higher than those in the control group, indicating that the combined scheme is effective in treating elderly multiple myeloma and can effectively improve the immune function of patients. Here, CD8A is linked to plasma cell myeloma.